No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.0x · 10Y median 0.9x · 60th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:21:18.825Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T13:21:18.825Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T13:21:18.825Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:21:18.825Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:21:18.825Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Clover Health Investments, Corp. (CLOV) stock was $4.68 as of Oct 5, 2026, 4:00 PM EDT, up 6.85% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +80.2% · 3-year avg +64.0%/yr · 5-year avg -8.4%/yr
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance.
Medical - Healthcare Plans · Wilmington, DE
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.01
Revenue Est.
$740.31M
Last Quarter Results
EPS
$0.07
vs Estimate
$0.05
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CLOV | $2.43B | $4.68 | +6.85% | +80.19% | -8.36% | N/A | N/A |
| 2IRON | $2.43B | $63.33 | -1.83% | -6.54% | +10.70% | N/A | vs CLOV |
| 3ADMA | $2.34B | $10.11 | +4.01% | -30.91% | +54.74% | +3.85% | vs CLOV |
| 4RXRX | $2.51B | $4.78 | +16.02% | -12.88% | -25.86% | N/A | vs CLOV |
| 5HRMY | $2.31B | $39.92 | +0.71% | +46.07% | +0.91% | N/A | vs CLOV |
| 6BEAM | $2.64B | $25.67 | +4.78% | -0.31% | -21.41% | N/A | vs CLOV |
forward FY estimate
83.51
$743.17M
vs Estimate
$728.27M
Consensus Rating
Based on 4 analysts
Average Price Target
$5.38
+14.9% upside
Low
$5.00
Current
$4.68
High
$6.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 1 |
| Quarter ending Dec 2026 | $-0.05 | $-0.05 | $-0.04 | 1 |
| Quarter ending Mar 2027 | $0.06 | $0.06 | $0.06 | 1 |
| Quarter ending Jun 2027 | $0.05 | $0.05 | $0.05 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.05 | $0.06 | $0.06 | 2 |
| FY 2027 | $0.10 | $0.10 | $0.10 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $737.80M | $740.31M | $743.58M | 2 |
| Quarter ending Dec 2026 | $721.02M | $723.47M | $726.67M | 2 |
| Quarter ending Mar 2027 | $900.38M | $903.44M | $907.43M | 1 |
| Quarter ending Jun 2027 | $888.37M | $891.40M | $895.33M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.91B | $2.95B | $2.99B | 3 |
| FY 2027 | $3.48B | $3.53B | $3.57B | 3 |
